Stockscreener 앱 받기
6.80
3.00%
-0.21
시간 외 거래:
6.92
0.12
+1.76%
전일 마감가:
$7.01
열려 있는:
$6.98
하루 거래량:
199.74K
Relative Volume:
2.04
시가총액:
$620.94M
수익:
$116.59M
순이익/손실:
$9.88M
주가수익비율:
302.22
EPS:
0.0225
순현금흐름:
$-2.40M
1주 성능:
-12.88%
1개월 성능:
-19.24%
6개월 성능:
-6.21%
1년 성능:
-33.85%
1일 변동 폭
$6.76
$7.03
1주일 범위
$6.76
$8.01
52주 변동 폭
$6.11
$11.78
Gyre Therapeutics Inc Stock (GYRE) Company Profile
명칭
Gyre Therapeutics Inc
전화
(858) 567-7770
주소
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.80 | 640.11M | 116.59M | 9.88M | -2.40M | 0.0225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | Jefferies | Buy |
| 2025-08-26 | 개시 | H.C. Wainwright | Buy |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
모두보기
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2%Time to Sell? - MarketBeat
Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN
China grants priority review to Gyre’s liver fibrosis drug - Investing.com
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - Bitget
Aug Intraday: Is Gyre Therapeutics Inc currently under institutional pressureTrade Ideas & Weekly Top Gainers Alerts - baoquankhu1.vn
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics, Inc. Announces China?s NMPA Grants Priority Review to the NDA for Hydronidone for CHB-Induced Liver Fibrosis Treatment - marketscreener.com
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions - The Globe and Mail
Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results - MarketBeat
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold - MarketBeat
Gyre Therapeutics 2025 10-K: Revenue $116.6M, Net Income Per Share Decline - TradingView
Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS
Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - Sahm
Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com
Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 earnings miss estimates - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap DownShould You Sell? - MarketBeat
Gyre Therapeutics (GYRE) Posts Q4 FY25 Loss of $0.02; misses estimates - AlphaStreet
Gyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Q4 Results Fall Short of Expectations - Bitget
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs - TipRanks
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates - Yahoo Finance
Gyre Therapeutics, Inc. Provides Revenues Outlook for 2026 - marketscreener.com
GYRE | Gyre Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Gyre Therapeutics Q4 revenue beats estimates on new product launch - TradingView
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases - marketscreener.com
Gyre Therapeutics (NASDAQ: GYRE) details F351, ETUARY and CG001419 outlook at investor conference - Stock Titan
Gyre Therapeutics reports fourth quarter and full year 2025 financial results - marketscreener.com
(GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Revenue $37.2M, vs. FactSet Est of $35.4M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS - marketscreener.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports 10% Revenue Growth in Full-Year 2025 and Announces Acquisition of Cullgen - Quiver Quantitative
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Biotech Gyre to add $300M degrader drug pipeline in 2026 deal - Stock Titan
Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Earnings Update: Can Gyre Therapeutics Inc maintain its current growth rateJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpTime to Buy? - MarketBeat
GYRE Technical Analysis & Stock Price Forecast - Intellectia AI
GYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance
Gyre Therapeutics to acquire Cullgen for $300 million By Investing.com - Investing.com Australia
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal - TipRanks
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2%Should You Buy? - MarketBeat
Gyre Therapeutics Inc (GYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):